A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

A Multi-cohort, Randomized Study in Healthy Subjects to Assess the Pharmacokinetics and Safety of Single and Multiple Ascending Doses of JNJ-61393215 (Suspension), and to Assess the Relative Bioavailability, and the Effect of Food on the Pharmacokinetics, of a New Solid Formulation (Capsules) of JNJ-61393215

The purpose of this 3 part study are; Part 1: to investigate the pharmacokinetic (PK), safety and tolerability of JNJ-61393215 suspension (ascending dose levels) after single oral dose administration under fasted conditions, Part 2: to evaluate the relative bioavailability of a solid JNJ-61393215 capsule formulation compared to a suspension of JNJ-61393215 under fasted conditions, and the effect of food on the PK of the solid JNJ-61393215 capsule formulation, Part 3: to investigate the PK, safety, and tolerability of JNJ-61393215 suspension (ascending dose levels) after 7 days of once daily dosing in under fasted conditions.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: JNJ-61393215; Drug: Placebo; Drug: JNJ-61393215

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands, NZ 9728
    • PRA Health Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or female of non-childbearing potential
• Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) (including QT interval corrected for heart rate according to Fridericia's formula [QTcF] less-than or equal to [<=] 450 milliseconds (ms) for males and <= 470 ms for females) performed at screening
• Before enrollment, female participants must be of non-childbearing potential, defined as: a) Postmenopausal - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause, as documented by medical records or physician's notes; b) Permanently sterile - Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy
• Body mass index (BMI) between 18 and 30 kilogram per square meter (kg/m^2) (inclusive), and body weight < than 50 kg at screening
• Blood pressure (after the participant is supine for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic at screening

Exclusion Criteria:

• Clinically significant abnormal values for hematology, biochemistry, or urinalysis at screening as deemed appropriate by the investigator
• Participants has any liver function test (including alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT], alkaline phosphatase [ALP], and bilirubin) at screening more than (>)1.5* upper limit of normal (ULN)
• Participants has estimated glomerular filtration rate (eGFR) according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation < 61 milliliter (mL) / minute /1.73 per square meter (m^2) at screening
• Clinically significant abnormal physical examination, vital signs, or 12 lead ECG at screening as deemed appropriate by the investigator
• Known allergies, hypersensitivity, or intolerance to JNJ-61393215 or its excipients (or lactose)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1 (Single Ascending Dose [SAD]): Cohort 1; Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: Placebo; Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 1 SAD: Cohort 2; Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: Placebo; Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 3: Treatment Sequence CDEF; Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 3: Treatment Sequence DFCE; Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 3: Treatment Sequence ECFD; Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 3: Treatment Sequence FEDC; Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 4: Treatment Sequence GHIJ; Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 4: Treatment Sequence HJGI; Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 4: Treatment Sequence IGJH; Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 2 Cohort 4: Treatment Sequence JIHG; Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 3 Cohort 5: Multiple Ascending Dose; Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: Placebo; Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Experimental: Part 3 Cohort 6: Multiple Ascending Dose; Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.	Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.; Drug: Placebo; Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.; Drug: JNJ-61393215; Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1: Maximum Observed Analyte Concentration (Cmax) of JNJ-61393215 Suspension	Cmax is defined as the maximum observed analyte concentration.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Time to Reach Maximum Observed Analyte Concentration (Tmax) of JNJ-61393215 Suspension	Tmax is defined as actual sampling time to reach maximum observed analyte concentration.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Area Under the Analyte Concentration-time Curve from Time Zero to the Time of Last Measurable Concentration (AUC[0-last]) of JNJ-61393215 Suspension	AUC(0-last) is defined as the area under the analyte concentration-time curve from time 0 to the time of the last measurable (non-below quantification level [non-BQL]) analyte concentration calculated by linear-linear trapezoidal summation.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Area Under the Analyte Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of JNJ-61393215 Suspension	AUC (0-infinity) is defined as the area under the analyte concentration vs. time curve from time 0 to infinite time, calculated as AUC(0-last) + Clast/lambda(z), where Clast is the last observed measurable (non-BQL) analyte concentration.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Apparent Terminal Elimination Rate Constant (lambda[z]) of JNJ-61393215 Suspension	lambda(z) is estimated by linear regression using the terminal logarithmic (log)-linear phase of the log transformed concentration vs time data.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Apparent Elimination Half-Life (t1/2) of JNJ-61393215 Suspension	T1/2 is defined as the apparent terminal elimination half-life and is calculated as 0.693/lambda(z).	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Apparent Oral Clearance (CL/F) of JNJ-61393215 Suspension	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Apparent Volume of Distribution (Vdz/F) of JNJ-61393215 Suspension	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired analyte concentration of a drug. Apparent volume of distribution after subcutaneous dose (Vz/F) is influenced by the fraction absorbed.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Part 1: Number of Participants with Adverse Events as a Measure of Safety and Tolerability of JNJ 61393215 Suspension	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Up to 7 Weeks
Part 2: Maximum Observed Analyte Concentration (Cmax) of JNJ-61393215 Capsule	Cmax is defined as the maximum observed analyte concentration.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose
Part 2: Area Under the Analyte Concentration-time Curve from Time Zero to the Time of Last Measurable Concentration (AUC[0-last]) of JNJ-61393215 Capsule	AUC(0-last) is defined as the area under the analyte concentration-time curve from time 0 to the time of the last measurable (non-below quantification level [non-BQL]) analyte concentration calculated by linear-linear trapezoidal summation.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose
Part 2: Area Under the Analyte Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of JNJ-61393215 Capsule	AUC(0-infinity) is defined as the area under the analyte concentration vs. time curve from time 0 to infinite time, calculated as AUC(0-last) + Clast/lambda(z), where Clast is the last observed measurable (non-BQL) analyte concentration.	Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose
Part 3: Maximum Observed Analyte Concentration (Cmax) of JNJ-61393215 Suspension	Cmax is defined as the maximum observed analyte concentration.	Predose, 20, 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6 and 12 hours postdose on Day 1 and Day 7; 24 and 48 hours postdose on Day 7
Part 3: Time to Reach Maximum Observed Analyte Concentration (Tmax) of JNJ-61393215 Suspension	Tmax is defined as actual sampling time to reach maximum observed analyte concentration.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours postdose on Day 1 and Day 7, 24 and 48 hours postdose on Day 7
Part 3: Area Under the Analyte Concentration-time Curve from Time 0 to 24 Hours (AUC [0-24]) of JNJ-61393215 Suspension	Area under the analyte concentration vs time curve from time 0 to 24 hours, calculated by linear-linear trapezoidal summation.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours postdose on Day 1 and Day 7, 24 hours postdose on Day 7
Part 3: Maximum Trough Concentration (Ctrough) of JNJ-61393215 Suspension	Ctrough is defined as the observed analyte concentration just prior to the beginning or at the end of a dosing interval. Ctrough estimation does not include the concentration that occurs just prior to the first dose.	Predose on day 1, 2, 3, 4, 5, 6, 7 and 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24 and 48 hours postdose on Day 7
Part 3: Minimum Observed Analyte Concentration (Cmin) of JNJ-61393215 Suspension	Cmin is defined as the minimum observed analyte concentration during the dosing interval.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24 and 48 hours postdose on Day 7
Part 3: Average Analyte Concentration (Cavg) of JNJ-61393215 Suspension	Cavg is defined as the value of the average analyte concentration at steady state over the dosing interval.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24 and 48 hours postdose on Day 7
Part 3: Fluctuation Index (FI) of JNJ-61393215 Suspension	FI is estimated as the percentage fluctuation (variation) between the maximum and minimum analyte concentration at steady state.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours postdose on Day 7
Part 3: Volume of Distribution at Steady-State (Vss) of JNJ-61393215 Suspension	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC[0-infinity])*(AUMC[0-infinity])/AUC[0-infinity]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the analyte concentration-time curve from time zero to infinite time.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours postdose on Day 7
Part 3: Apparent Oral Clearance (CL/F) of JNJ-61393215 Suspension	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours postdose on Day 7
Part 3: Apparent Terminal Elimination Rate Constant (lambda[z]) of JNJ-61393215 Suspension	lambda(z) is estimated by linear regression using the terminal logarithmic (log)-linear phase of the log transformed concentration vs time data.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours postdose on Day 7
Part 3: Apparent Elimination Half-Life (t1/2) of JNJ-61393215 Suspension	T1/2 is defined as the apparent terminal elimination half-life and is calculated as 0.693/lambda(z).	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours postdose on Day 7
Part 3: Peak by Trough Ratio of JNJ-61393215 Suspension	Peak by trough ratio is defined as the ratio of the maximum observed analyte concentration to the minimum observed analyte concentration.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours postdose on Day 7
Part 3: Observed Accumulation Index Based on AUC (AR AUC) of JNJ-61393215 Suspension	AR AUC is determined after multiple-dose administration and calculated as AUC (0-24h) on day 7 divided by AUC (0-24h) on day 1.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose on Day 1 and 7
Part 3: Observed Accumulation Index Based on Cmax (ARCmax) of JNJ-61393215 Suspension	ARCmax is determined after multiple-dose administration and calculated as Cmax on day 7 divided by Cmax on day 1.	Predose, 20 and 40 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose on Day 1 and 7

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 2: Number of Participants with Adverse Events as a Measure of Safety and Tolerability of JNJ 61393215	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Up to 8 Weeks

Collaborators and Investigators

• Sponsor: Janssen Research & Development, LLC
• Investigators: Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Study record dates

Study Major Dates

• Study Start (Actual): August 28, 2018
• Primary Completion (Actual): December 14, 2018
• Study Completion (Actual): December 14, 2018

Study Registration Dates

• First Submitted: August 27, 2018
• First Submitted That Met QC Criteria: August 27, 2018
• First Posted (Actual): August 28, 2018

Study Record Updates

• Last Update Posted (Actual): April 27, 2025
• Last Update Submitted That Met QC Criteria: April 25, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: CR108492; 2018-001944-80 (EudraCT Number); 61393215EDI1004 (Other Identifier: Janssen Research & Development, LLC)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No